Substandard Medicine Shipment With Repeated Quality Failures

A shipment of Budecort 0.5 mg Respules moving from India to Oman appeared to be a routine pharmaceutical import.

At first glance, the shipment included standard declaration details: exporter, importer, route, product description, HS code, quantity, value, and reefer transport information. But Publican flagged the shipment for inspection after identifying multiple risk indicators, including alerted web results and substandard medicine.

The shipment overview shows Publican’s vetting result: Inspect, with substandard medicine listed as one of the key reasons for escalation. The system also shows cross-entity alerts, indicating that the risk was connected not only to the shipment itself, but also to the manufacturer and product history.

Publican then analyzed the manufacturer’s pharmaceutical quality record. The system found that Cipla Limited had been associated with multiple medicines that did not meet standard quality requirements.

The substandard-products analysis shows several quality-related findings across different products, including assay and identification issues. Importantly, the list includes Budecort Respules, the same product family as the shipment under review.

Publican also expanded the historical view and surfaced additional quality failures across multiple years. These included issues such as assay failures, hardness, uniformity of dispersion, and identification problems.

This broader history showed that the risk was not based on a single isolated event. Publican identified a repeated pattern of medicine-quality concerns connected to the manufacturer, strengthening the case for inspection.

Publican then added external web and legal intelligence to provide broader context around the company’s compliance and reputation profile. The system surfaced alerted web pages connected to legal, patent, and reputational issues involving the manufacturer.

The alerted web results helped support the risk assessment by showing that the company had broader compliance-related signals beyond the specific shipment. Combined with the product-quality findings, this created a stronger basis for escalation.

By connecting the declared medicine shipment, manufacturer history, product-level quality failures, lab-related findings, and external web intelligence, Publican elevated a routine pharmaceutical shipment into a high-priority public-health risk case before clearance.

Why It Matters

Substandard medicine can put patients at serious risk when products fail identity, potency, or quality requirements. Importing authorities may not always have access to the manufacturer’s full global compliance and quality history.

Publican helps close that gap by connecting shipment data with regulatory findings, product-quality records, manufacturer-risk indicators, and external intelligence.

Publican Capabilities Shown

Substandard Medicine Detection

Flags medicines linked to failed quality checks, lab findings, or regulatory alerts.
Manufacturer Risk Profiling

Connects shipments to the manufacturer’s historical quality and compliance record.
Product-Level Risk Matching

 Identifies when the shipped product or related product family appears in prior quality alerts.
Regulatory Alert Intelligence

Surfaces findings such as assay, identification, hardness, and uniformity failures.
External Source Verification

Uses alerted web results and legal sources to support the risk assessment.
Public Health Risk Screening

Prioritizes pharmaceutical shipments that may pose patient-safety concerns.